PVI is a payer-centered platform that supports a more consistent, transparent and efficient review of clinical, economic and patient-centered evidence. Watch a demo of the platform.
Best Practice Handout – Health Plan Best Practice – Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)
Summary Framework for Improving Precision Oncology in NSCLC Findings From The AMCP Market Insights Program
The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.
For more disease state research, view the Market Insights Program.
Related
AMCP's Q3 2026 Precision Medicine Bulletin is now available, featuring a recap of key precision medicine developments from 2026, a review of recent clinical guidelines, highlights from new publications in the field, and updates on AMCP's submission to the National Comprehensive Cancer Network (NCCN).
Pharmacy benefit manager (PBM) reform is evolving rapidly at the state level, creating a complex and often fragmented policy landscape that stakeholders must actively monitor. Understanding which reforms are advancing in each state is critical, as these policies can significantly alter drug pricing dynamics, rebate structures, formulary design, and patient access.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
